Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review-Reference-Cited by-同舟云学术

Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review

Published:2022-11 Issue: Volume:16 Page:100210
ISSN:2590-1702
Container-title:Clinical Infection in Practice
language:en
Short-container-title:Clinical Infection in Practice

Author:

Hettle David,Hutchings Stephanie,Muir Peter,Moran Ed

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference74 articles.

1. ACTIV-3-Therapeutics for Inpatients with COVID-19 (TICO) Study Group, 2022. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med 2022;10(10):972-84.

2. Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: a case report;Arai;J Infect Chemother,2022

3. Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue;Arcani;Ann Hematol,2021

4. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient;Baang;J Infect Dis,2021

5. Persistent coronavirus disease 2019 (COVID-19) in an immunocompromised host treated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies;Bailly;Clin Infect Dis,2022

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistent COVID-19 Infection in an Immunocompromised Host: A Case Report;Cureus;2024-09-04

2. Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation;Molecular Therapy - Methods & Clinical Development;2024-09

3. CD4 ⁺ and CD8 ⁺ T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment;Science Advances;2024-08-23

4. Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series;Open Forum Infectious Diseases;2024-07-30

5. A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments;AM J CASE REP;2024